Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.

AUTOR(ES)

Clumeck, N

RESUMO

Ceftazidime was administered intravenously or intramuscularly or both in doses of 1 to 6 g per day to 33 patients with serious gram-negative bacillary infections (12 pulmonary, 10 urinary tract, 4 soft tissue, 4 intraabdominal, and 3 miscellaneous infections). Twenty-one patients were septicemic. We identified 20 isolates of members of the family Enterobacteriaceae and 13 isolates of Pseudomonas aeruginosa. Seventeen patients had failed to respond to previous antimicrobial therapy. A total of 23 patients were clinically cured, 7 patients improved, and 3 patients failed to respond to therapy. The selection or emergence of resistant organisms during treatment (mostly Candida spp., Staphylococcus aureus, and enterococci) was noted in 11 patients. Toxicity was minimal (reversible mild liver function abnormalities and eosinophilia). The results of this study suggest that ceftazidime is an effective and well-tolerated new cephalosporin for the therapy of serious infections due to susceptible gram-negative organisms.

Documentos Relacionados

• Ceftazidime therapy of serious bacterial infections.
• Moxalactam in the therapy of serious infections.
• Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome.
• An overview of nosocomial infections, including the role of the microbiology laboratory.
• Vaccine and Serum Therapy, Including also a Study of Infections, Theories of Immunity, Specific Diagnosis and Chemotherapy